Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX Market Closed
Updated: Jun 2, 2024

Dechra Pharmaceuticals PLC
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dechra Pharmaceuticals PLC
Cost of Revenue Peer Comparison

Comparables:
GSK
AZN
VRNA
INDV
HIK

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Dechra Pharmaceuticals PLC
LSE:DPH
Cost of Revenue
-£331.9m
CAGR 3-Years
-14%
CAGR 5-Years
-13%
CAGR 10-Years
-14%
GlaxoSmithKline PLC
LSE:GSK
Cost of Revenue
-£8.4B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
-1%
AstraZeneca PLC
LSE:AZN
Cost of Revenue
-$8.5B
CAGR 3-Years
-14%
CAGR 5-Years
-14%
CAGR 10-Years
-5%
Verona Pharma PLC
NASDAQ:VRNA
Cost of Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Cost of Revenue
-$193m
CAGR 3-Years
-21%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Cost of Revenue
-$1.5B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-9%

See Also

What is Dechra Pharmaceuticals PLC's Cost of Revenue?
Cost of Revenue
-331.9m GBP

Based on the financial report for Jun 30, 2023, Dechra Pharmaceuticals PLC's Cost of Revenue amounts to -331.9m GBP.

What is Dechra Pharmaceuticals PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-14%

Over the last year, the Cost of Revenue growth was -12%. The average annual Cost of Revenue growth rates for Dechra Pharmaceuticals PLC have been -14% over the past three years , -13% over the past five years , and -14% over the past ten years .